ANERIA Trademark

Trademark Overview


On Tuesday, March 17, 2020, a trademark application was filed for ANERIA with the United States Patent and Trademark Office. The USPTO has given the ANERIA trademark a serial number of 88837767. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 4, 2022. This trademark is owned by Allergan Pharmaceuticals International Limited. The ANERIA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
aneria

General Information


Serial Number88837767
Word MarkANERIA
Filing DateTuesday, March 17, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 4, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 7, 2020

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, March 21, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Pharmaceuticals International Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDublin 17 07940
IE

Party NameAllergan Pharmaceuticals International Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDublin 17 07940
IE

Trademark Events


Event DateEvent Description
Monday, April 4, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 4, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, August 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 6, 2021EXTENSION 2 GRANTED
Friday, August 6, 2021EXTENSION 2 FILED
Friday, August 6, 2021TEAS EXTENSION RECEIVED
Tuesday, March 2, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 26, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, February 26, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, February 26, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, February 26, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, February 26, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, February 26, 2021EXTENSION 1 GRANTED
Friday, February 26, 2021EXTENSION 1 FILED
Friday, February 26, 2021TEAS EXTENSION RECEIVED
Thursday, February 25, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 25, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 25, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 1, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 7, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 7, 2020PUBLISHED FOR OPPOSITION
Wednesday, June 17, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 3, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 27, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 27, 2020NON-FINAL ACTION E-MAILED
Wednesday, May 27, 2020NON-FINAL ACTION WRITTEN
Friday, May 22, 2020ASSIGNED TO EXAMINER
Saturday, March 21, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, March 20, 2020NEW APPLICATION ENTERED IN TRAM